112 related articles for article (PubMed ID: 36989865)
21. Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.
Suenaga N; Kuramitsu M; Komure K; Kanemaru A; Takano K; Ozeki K; Nishimura Y; Yoshida R; Nakayama H; Shinriki S; Saito H; Jono H
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635163
[TBL] [Abstract][Full Text] [Related]
22. CerS6 regulates cisplatin resistance in oral squamous cell carcinoma by altering mitochondrial fission and autophagy.
Li S; Wu Y; Ding Y; Yu M; Ai Z
J Cell Physiol; 2018 Dec; 233(12):9416-9425. PubMed ID: 30054909
[TBL] [Abstract][Full Text] [Related]
23. Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells.
Liu YK; Jia YJ; Liu SH; Shi HJ; Ma J
Histol Histopathol; 2021 May; 36(5):535-545. PubMed ID: 33570156
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1.
Li P; Yang X; Cheng Y; Zhang X; Yang C; Deng X; Li P; Tao J; Yang H; Wei J; Tang J; Yuan W; Lu Q; Xu X; Gu M
Cell Physiol Biochem; 2017; 41(3):921-932. PubMed ID: 28222430
[TBL] [Abstract][Full Text] [Related]
25. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
[TBL] [Abstract][Full Text] [Related]
26. BCAT1 overexpression regulates proliferation and c‑Myc/GLUT1 signaling in head and neck squamous cell carcinoma.
Wang H; Wang F; Ouyang W; Jiang X; Wang Y
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760210
[TBL] [Abstract][Full Text] [Related]
27. Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia.
Shimanishi M; Ogi K; Sogabe Y; Kaneko T; Dehari H; Miyazaki A; Hiratsuka H
J Oral Pathol Med; 2013 May; 42(5):382-8. PubMed ID: 23227892
[TBL] [Abstract][Full Text] [Related]
28. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
29. MiR-200c inhibited the proliferation of oral squamous cell carcinoma cells by targeting Akt pathway and its downstream Glut1.
Yan Y; Yan F; Huang Q
Arch Oral Biol; 2018 Dec; 96():52-57. PubMed ID: 30179745
[TBL] [Abstract][Full Text] [Related]
30. miR-21 inhibitor sensitizes human OSCC cells to cisplatin.
Wang W; Songlin P; Sun Y; Zhang B; Jinhui W
Mol Biol Rep; 2012 May; 39(5):5481-5. PubMed ID: 22249446
[TBL] [Abstract][Full Text] [Related]
31. Long noncoding RNA CEBPA-DT promotes cisplatin chemo-resistance through CEBPA/BCL2 mediated apoptosis in oral squamous cellular cancer.
Qiao X; Liu J; Zhu L; Song R; Zhong M; Guo Y
Int J Med Sci; 2021; 18(16):3728-3737. PubMed ID: 34790046
[TBL] [Abstract][Full Text] [Related]
32. ARL6IP5 reduces cisplatin-resistance by suppressing DNA repair and promoting apoptosis pathways in ovarian carcinoma.
Kim JY; Bahar E; Lee JY; Chang S; Kim SH; Park EY; Do SI; Yoon H; Kim HS
Cell Death Dis; 2022 Mar; 13(3):239. PubMed ID: 35293383
[TBL] [Abstract][Full Text] [Related]
33. Long noncoding RNA PVT1 promotes tumor cell proliferation, invasion, migration and inhibits apoptosis in oral squamous cell carcinoma by regulating miR‑150‑5p/GLUT‑1.
Li X; Ren H
Oncol Rep; 2020 Oct; 44(4):1524-1538. PubMed ID: 32945498
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of microRNA-218 promotes oral squamous cell carcinoma growth by targeting GLUT1 to affect glucose metabolism.
Xu XJ; Yuan J; Sun WJ; Chen QY; Lin Y; Tang L; Liang LZ
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7726-7734. PubMed ID: 30536316
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin Induced the Expression of
Li J; Vangundy Z; Poi M
Anticancer Res; 2020 Jan; 40(1):67-73. PubMed ID: 31892553
[TBL] [Abstract][Full Text] [Related]
36. Combinatorial treatment with Gefitinib and Bay11-7085 sensitizes primary Gefitinib-resistant OSCC cells by influencing the EGFR- NFκB signaling axis.
Sinto MS; Thomas S; Kannan S
Med Oncol; 2021 Aug; 38(9):110. PubMed ID: 34357463
[TBL] [Abstract][Full Text] [Related]
37. Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma.
Tsai LL; Yu CC; Chang YC; Yu CH; Chou MY
J Oral Pathol Med; 2011 Sep; 40(8):621-8. PubMed ID: 21342274
[TBL] [Abstract][Full Text] [Related]
38. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of IGFBP-2 improves the sensitivity of bladder cancer cells to cisplatin via upregulating the expression of maspin.
Zhu H; Yun F; Shi X; Wang D
Int J Mol Med; 2015 Aug; 36(2):595-601. PubMed ID: 26080829
[TBL] [Abstract][Full Text] [Related]
40. MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1.
Chen L; Zhu Q; Lu L; Liu Y
Bioengineered; 2020 Dec; 11(1):91-102. PubMed ID: 31906769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
